PPCB — Propanc Biopharma, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1517681 ·
Last close
$1.88
Market Cap
$1.94M
52W High
$315.00
52W Low
$1.63
ADV30
36,167
Next earnings
—
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertake research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP. Propanc Biopharma, Inc. was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. The company was incorporated in 2007 and is based in Camberwell, Australia.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -3,457,050 -4,573,242 12,779,912 832,006 3,378,251
Mar 2026 0 — -6,400,221 -6,360,336 14,333,780 443,702 3,505,895
Dec 2025 0 — -3,654,734 -3,091,394 15,111,532 561,237 3,659,267
Sep 2025 0 — -4,673,564 -4,837,738 17,975,681 602,737 3,614,514

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-5,682,635
Investing CF
$-4,933
Financing CF
$6,457,298
CapEx
$-4,933
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-336.75
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-144,484,230
Inventory
—
Receivables
$13,694
ST Investments
—
EBIT TTM
$-18,432,171
Pretax Income TTM
$-18,862,710
Interest Exp TTM
$430,539
Analysts
—

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Jun 2026 0 -18,185,569 -18,862,710 12,779,912 3,378,251 9,401,661 -5,682,635
Jun 2025 — — — — — — —
Jun 2024 0 -1,536,049 -1,820,528 72,365 3,851,424 -3,779,059 -935,118
Jun 2023 0 -1,776,645 -2,660,566 60,300 3,177,507 -3,117,179 -1,105,251
Jun 2022 0 -1,990,870 -2,658,087 81,651 3,105,300 -3,023,649 -1,436,304

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-18,862,710
OpCashFlow TTM
—
Assets (Latest)
$14,333,780
Forward EPS
—

Peers — same industry

TickerNameMarket CapLastDaily %
XRTX XORTX Therapeutics Inc. $1.93M $1.06 —
JAGX Jaguar Health, Inc. $1.96M $0.38 —
ACUT Accustem Sciences Inc. $1.90M $0.12 —
JUNS JUPITER NEUROSCIENCES, INC. $2.00M $1.52 —
SXTP 60 DEGREES PHARMACEUTICALS, INC. $1.88M $0.53 —

News headlines (Yahoo Finance, 1h cache)

Propanc Biopharma Reports Preclinical Data with PRP & PRP plus TGF-β Inhibitor on TGF-β Pathway in Pancreatic Cancer
2026-11-02 13:30 · Yahoo
Propanc Biopharma Advances Bioanalytical & Immunogenicity Assay Development for Phase 1b First-In-Human Study in up to 50 Advanced Cancer Patients
2026-10-30 12:30 · Yahoo
Propanc Biopharma Advances Clinical Development Preparation for PRP Phase 1b First-In-Human Study in Up to 50 Advanced Cancer Patients
2026-10-28 12:30 · Yahoo
Propanc Biopharma Publishes New Data: PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells & Restores Therapeutic Vulnerability
2026-10-26 12:30 · Yahoo
CORRECTION -- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
2026-10-22 20:24 · Yahoo
Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
2026-10-22 12:30 · Yahoo
Propanc Biopharma’s Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells
2026-10-16 12:36 · Yahoo
Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer
2026-10-14 12:30 · Yahoo
Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results
2026-09-29 12:30 · Yahoo
Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015
2026-09-22 12:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.